What is the difference between carrier-added and no-carrier-added radionuclides?
The difference between carrier-added and no-carrier-added radionuclides relates to whether stable (non-radioactive) atoms of the same element are present alongside the radioactive isotope.
In a carrier-added preparation, the radioactive isotope is mixed with a significant quantity of stable atoms of the same element. In a no-carrier-added (NCA) preparation, the radioactive isotope is produced and isolated without the presence of stable atoms of the same element, resulting in much higher specific activity.
Carrier-added radionuclides contain stable atoms of the same element and have lower specific activity, whereas no-carrier-added radionuclides are isolated without stable carrier and have higher specific activity.
This distinction affects specific activity, receptor binding, and labelling efficiency.
Understanding the physics
Specific activity describes the amount of radioactivity per unit mass. Whether a radionuclide is carrier-added or no-carrier-added directly determines its specific activity.
In neutron capture reactions inside a reactor, a stable nucleus absorbs a neutron and becomes radioactive. However, the product remains chemically identical to the target material. This means radioactive atoms are mixed with a large amount of stable atoms of the same element. The result is carrier-added material with lower specific activity.
In contrast, cyclotron production often allows chemical separation of the radioactive isotope from the target material. Because the radioactive atoms are isolated without stable atoms of the same element, the product is effectively no-carrier-added, resulting in high specific activity.
Why does this matter?
If a radiopharmaceutical targets a limited number of biological receptors, the presence of stable (non-radioactive) carrier atoms may compete for binding sites. This can reduce tracer uptake and decrease image sensitivity. High specific activity (no-carrier-added) preparations minimise this competitive effect.
For many PET tracers such as F-18 FDG, production is effectively no-carrier-added, which allows highly efficient labelling and sensitive detection.
Where this matters clinically
High specific activity is particularly important for receptor imaging and peptide-based tracers, where binding site saturation could reduce diagnostic accuracy.
Understanding the difference between carrier-added and no-carrier-added preparations also explains variability in labelling efficiency and tracer performance.